Table 2.
First-line treatment groups (n = 178), with the TTNT after first-line systemic therapies (n = 169)
| First-line treatment groups | N = 178 first-line treatments (%) | Median TTNT (months) for first-line systemic therapies (95% CI) | % free from next line of treatment at 1 year (95% CI) | % free from next line of treatment at 2 years (95% CI) |
|---|---|---|---|---|
| Monotherapies | ||||
| Extracorporeal photopheresis (ECP) monotherapy | 16 (9.0) | 8.0 (2.0-10.7) | 20.8 (5.2-43.6) | 20.8 (5.2-43.6) |
| Histone deacetylase (HDAC) inhibitor monotherapy | 4 (2.3) | 3.6 | 25 (0.9-66.5) | 25 (0.9-66.5) |
| Interferon monotherapy | 21 (11.8) | 4.8 (3.0-7.4) | 14.3 (3.6-32.1) | 4.8 (0.3-19.7) |
| Methotrexate monotherapy | 28 (15.7) | 5.0 (3.0-7.4) | 26.8 (12.0-44.1) | 15.3 (4.9-31.2) |
| Monoclonal antibody–based monotherapy∗ | 4 (2.3) | 2.0 | 0 | 0 |
| Retinoid monotherapy | 33 (18.5) | 4.4 (3.2-7.7) | 24.2 (11.4-39.6) | 6.1 (1.1-17.6) |
| Systemic chemotherapy, multiagent monotherapy | 8 (4.5) | 4.7 (0.5-6.0) | 0 | 0 |
| Systemic chemotherapy, single-agent monotherapy† | 14 (7.9) | 4.9 (2.4-7.0) | 0 | 0 |
| Combination therapies | ||||
| ECP–based combination therapy | 36 (20.2) | 9.8 (6.3-12.5) | 40.1 (24.0-55.8) | 14.9 (40.9-30.0) |
| Interferon–based combination therapy | 4 (2.3) | 9.2 | 50.0 (5.8-84.5) | 50.0 (5.8-84.5) |
| Other combinations of systemic therapies | 1 (0.6) | — | 0 | 0 |
| Non-systemic therapies | ||||
| Skin–directed monotherapy only | 4 (2.3) | — | — | — |
| Supportive care only | 5 (2.8) | — | — | — |
∗
Alemtuzumab, 4
†
Excluding low dose methotrexate monotherapy